+ Watch TKMR
on My Watchlist
Biotech focused on RNA technology and RNAi therapeutics. Has secured licenses to develop treatment for Alcohol Dependance (AD), an Ebola Vaccine, and various oncology applications. Has agreement with Merck and Alnylam Pharmaceuticals, and in collaboration with US government.
Let your winners run...TKMR is a winner.
Cheap RNAi platform. Need to leverage their platform out and focus on some bigger targets than Ebola. The stock is very cheap relative to its peers...especially ALNY
Following porte and ZZ.
I felt like giving it a red thumb just to be the first one, but no, this looks pretty good.
A "penny" stock with improving technicals and no active All-Star red thumbs.
Tekmira is significantly undervalued, with 3 RNAi products in the clinical pipeline or about to start clinical trials, to include a product aimed at a strain of Zaire ebola under a DOD contract worth up to nearly $170 million. Tekmira's business model is well thought out -- use revenues earned from its RNAi delivery technology to fund its clinical trials and R&D. Tekmira has 5 additional siRNA payload compounds to pick from Alnylam's siRNA technology under very favorable terms. Each of those picks are well worth $5 to 10 million. Tekmira has collaboration or license agreements with some big pharma, to include Merck, Bristol Meyers Squibb, and Takeda. At about $28 million market cap, it's a screaming buy. The only real overhang/cloud is its ongoing litigation with Alnylam, which hopefully will be resolved sooner rather than later -- this will resolve the protection of Tekmira's lipid nanoparticle (LNP) intellectual property.
RNAi is an extremely complex field, and I don't claim to have a good understanding of the intellectual property issues currently at the heart of Tekmira's valuation. What I do see is that the company has lost more than half their market cap since they began trading on the Nasdaq last November, and the current 29M cap seems better suited to scams and companies on the verge of bankruptcy. But no matter whose side you take in the controversy between Tekmira and Alnylam, it seems that Tekmira is being undervalued considering the weight of their contribution to the field thus far. They also have three proprietary RNAi compounds in or on the verge of clinical development for diverse indications. Cash was 12M as of the end of 2010 and their quarterly burn rate is unclear, which may become an issue. A pervasive negative attitude about RNAi in recent months may also be dragging down the share price. Portefeuille obviously believes in this stub strongly, and I think this one may be more FOLD than PARD.
see this post.http://caps.fool.com/Blogs/tkmr/558889.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions